RayKnowChina Research Map
Shortlist0

Enrolling by invitationNasopharyngeal carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Xiamen University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06688175, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 65 years to 80 years; sex: all

    Registered eligibility fields

  2. Pathologically confirmed differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma;

    Inclusion criterion 1

  3. Stage II-IVa (UICC 8th edition);

    Inclusion criterion 2

  4. Liver function: Total bilirubin ≤ Upper Limit of Normal (ULN); AST and ALT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 5 times ULN;

    Inclusion criterion 6

    Renal function: Creatinine clearance ≥ 60 ml/min or Creatinine ≤ 1.5 × ULN;

    Inclusion criterion 7

    Hematological tests: Absolute Neutrophil Count (ANC) ≥ 2 × 10\^9/L, Platelet count ≥ 100 × 10\^9/L, and Hemoglobin ≥ 9 g/dL;

    Inclusion criterion 8

    Laboratory tests: Total bilirubin > Upper Limit of Normal (ULN); AST and/or ALT > 1.5 times ULN with alkaline phosphatase > 2.5 times ULN;

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06688175, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Pathologically confirmed differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma;
  • Stage II-IVa (UICC 8th edition);
  • Acceptable induction chemotherapy and Tarceva targeted therapy;
  • No history of other malignant tumors;
  • Male or female, aged 65-80 years.
  • Liver function: Total bilirubin ≤ Upper Limit of Normal (ULN); AST and ALT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 5 times ULN;
  • Renal function: Creatinine clearance ≥ 60 ml/min or Creatinine ≤ 1.5 × ULN;
  • Hematological tests: Absolute Neutrophil Count (ANC) ≥ 2 × 10\^9/L, Platelet count ≥ 100 × 10\^9/L, and Hemoglobin ≥ 9 g/dL;
  • No severe dysfunction of vital organs such as heart and lung;
  • PS score ≤ 2 points

Exclusion Criteria:

  • Distant metastases detected before treatment;
  • Refusal to sign the informed consent form;
  • Patients who cannot comply with regular follow-up due to psychological, social, family, or geographical reasons;
  • Simultaneously receiving other experimental treatments in clinical trials (during the treatment phase of clinical research);
  • Severe, uncontrolled infections or medical conditions;
  • Vital organ dysfunction, decompensated heart, lung, kidney, or liver failure, unable to tolerate radiotherapy and chemotherapy;
  • Laboratory tests: Total bilirubin > Upper Limit of Normal (ULN); AST and/or ALT > 1.5 times ULN with alkaline phosphatase > 2.5 times ULN;
  • Factors affecting drug administration, distribution, metabolism, and excretion, such as mental abnormalities, central nervous system abnormalities, chronic diarrhea, ascites, pleural effusion, etc.;
  • Long-term use of immunosuppressants after organ transplantation;
  • Patients with a history of other malignant tumors before enrollment.

Quoted from ClinicalTrials.gov, NCT06688175, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06688175, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06688175